Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

List of clinical trials for Exenatide

Exenatide
Exenatide Synthetic

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

Contact Supplier

Inke S.A: APIs manufacturing plant.

Contact Supplier

xyz-pharma-2025-04-21

Post An Enquiry

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

With Fermion, start the journey of your innovative API.

Contact Supplier

jdmfs-not-supported-m-2025-04-28

Post An Enquiry

Filters

FILTER :

filter Interventions

All

Exenatide

Insulin

filter Therapeutic Area

All

Endocrinology

filter Condition

All

Type 2 diabetes mellitus

filter Study Phase

All

Phase I

Undisclosed

filter Location

All

Blank

Oramed Pharmaceuticals

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

U.s.a

Digital Content

Single-blind, placebo-controlled, crossover study to evaluate safety in addition to the pharmacokinetics of ORMD-0901 compared to placebo an...

Highest Development Status: Phase I

Therapeutic Area: Endocrinology

Interventions: Exenatide

Product Type: Large molecule

Sponsor: Oramed Inc

Receptors: Glucagon-like peptide 1 recept...

Trial ID: NA

Location: NA

Condition: Type 2 diabetes mellitus

Product Status: Approved

Dosage Form: Capsule

Collaborator: NA

Recruitment Status: NA

Date Of Registration: NA

Product Description: ORMD-0901 (Exenatide), a GLP-1 analog, is based on Oramed

01

Oramed Pharmaceuticals

U.S.A

AMWC Asia-TDAC

Not Confirmed

Oramed Pharmaceuticals

U.S.A

AMWC Asia-TDAC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Highest Development Status: Phase I

Therapeutic Area: Endocrinology

Interventions: Exenatide

Location: NA

Sponsor: Oramed Inc

Trial ID: NA

Single-blind, placebo-controlled, crossover study to evaluate safety in addition to the pharmacokinetics of ORMD-0901 compared to placebo and to open label Byetta

Product Description: ORMD-0901 (Exenatide), a GLP-1 analog, is based on Oramed

Product Status: Approved

Dosage Form: Capsule

Collaborator: NA

Recruitment Status: NA

Date Of Registration: NA

Condition: Type 2 diabetes mellitus

Product Type: Large molecule

Receptors: Glucagon-like peptide 1 receptor agoni...

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Oramed Pharmaceuticals

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

U.s.a

Digital Content

Oral Combination Therapy for the Management of T2DM, by Combining the Advantages of ORMD-0801 and ORMD-0901

Highest Development Status: Undisclosed

Therapeutic Area: Endocrinology

Interventions: Exenatide,Insulin

Product Type: Large molecule

Sponsor: Oramed Inc

Receptors: Insulin receptor agonist||Gluc...

Trial ID: NA

Location: NA

Condition: Type 2 diabetes mellitus

Product Status: Approved

Dosage Form: Oral

Collaborator: NA

Recruitment Status: NA

Date Of Registration: NA

Product Description: ORMD-0801 (Oral Insulin) capsule and ORMD-0901 (Exenatide), a GLP-1 analog are pursuing an oral combination therapy for the management of T2DM without an increased risk for hypoglycemia.

02

Oramed Pharmaceuticals

U.S.A

AMWC Asia-TDAC

Not Confirmed

Oramed Pharmaceuticals

U.S.A

AMWC Asia-TDAC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Highest Development Status: Undisclosed

Therapeutic Area: Endocrinology

Interventions: Exenatide,Insulin

Location: NA

Sponsor: Oramed Inc

Trial ID: NA

Oral Combination Therapy for the Management of T2DM, by Combining the Advantages of ORMD-0801 and ORMD-0901

Product Description: ORMD-0801 (Oral Insulin) capsule and ORMD-0901 (Exenatide), a GLP-1 analog are pursuing an oral combination therapy for the management of T2DM without an increased risk for hypoglycemia.

Product Status: Approved

Dosage Form: Oral

Collaborator: NA

Recruitment Status: NA

Date Of Registration: NA

Condition: Type 2 diabetes mellitus

Product Type: Large molecule

Receptors: Insulin receptor agonist||Glucagon-lik...

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

First

Last